PI3K pathway-directed therapeutic strategies in cancer

Roshan Agarwal; Mark Carey; Bryan Hennessy; Gordon B. Mills

PI3K pathway-directed therapeutic strategies in cancer

Roshan Agarwal, Mark Carey, Bryan Hennessy, Gordon B. Mills

Research output: Contribution to journal › Review article › peer-review

Abstract

PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.

Original language	English (US)
Pages (from-to)	615-628
Number of pages	14
Journal	Current Opinion in Investigational Drugs
Volume	11
Issue number	6
State	Published - Jun 2010
Externally published	Yes

Keywords

Akt
Cancer
Drug development
Growth factor signaling
PI3K
Phase I clinical trial
Targeted therapy

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Cite this

@article{bf9d58ed392246229072ea71b0622cab,

title = "PI3K pathway-directed therapeutic strategies in cancer",

abstract = "PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.",

keywords = "Akt, Cancer, Drug development, Growth factor signaling, PI3K, Phase I clinical trial, Targeted therapy",

author = "Roshan Agarwal and Mark Carey and Bryan Hennessy and Mills, {Gordon B.}",

year = "2010",

month = jun,

language = "English (US)",

volume = "11",

pages = "615--628",

journal = "Current Opinion in Investigational Drugs",

issn = "1472-4472",

publisher = "Current Drugs Ltd.",

number = "6",

}

TY - JOUR

T1 - PI3K pathway-directed therapeutic strategies in cancer

AU - Agarwal, Roshan

AU - Carey, Mark

AU - Hennessy, Bryan

AU - Mills, Gordon B.

PY - 2010/6

Y1 - 2010/6

N2 - PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.

AB - PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.

KW - Akt

KW - Cancer

KW - Drug development

KW - Growth factor signaling

KW - PI3K

KW - Phase I clinical trial

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77952936573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952936573&partnerID=8YFLogxK

M3 - Review article

C2 - 20496256

AN - SCOPUS:77952936573

SN - 1472-4472

VL - 11

SP - 615

EP - 628

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

IS - 6

ER -

PI3K pathway-directed therapeutic strategies in cancer

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this